OftalMedica has been distributing technology for ophthalmologists in Italy since 2009, focusing on innovative cutting edge technology and high quality products” says Benedetto Sgroi, CEO of OftalMedica-
“We are very happy that Oculate will represent us in the growing market in South Africa and are confident that they will be successful with Vivior,” outlines Mario Stark, CEO of Vivior.
After testing our service in multiple settings and starting the market introduction in Europe, we are now ready to expand this through multiple partnerships with distributors, clinics and practices for a truly global reach.
Both Swiss companies agreed to collaborate in the field of personalized multifocal soft contact lenses for presbyopia correction. The objective is to optimize the design in soft multifocal contact lenses by using the data generated by Vivior’s visual behavior monitor, the Vivior Monitor.
Vivior's solution for measuring vision needs and supporting eye care professionals in selecting the optimal vision correction solution has passed a significant regulatory stepping-stone in the US.
Vivior launches its first product, the Vivior Monitor, at the meeting of the ESCRS (European Society of Cataract & Refractive Surgery).
The software uses state-of-the-art Artificial Intelligence to recognize activities and optimize lens selection for the ophthalmic surgeon.
In a test, Vivior determined individual visual habits using the Vivior Visual Behavior Monitor and, based on this objective data, provided customized vision correction lenses to each of the test participants.
Vivior has cleared their system as a Class I medical device and is planning the market introduction later this year in Switzerland and the European Union.
Michael Mrochen, PhD, Chairman of the Board of Directors at Vivior, receives the Casebeer Award from the International Society of Refractive Surgery.
Vivior has recently closed an investment round with private investors from Europe and the US. With multiple million USD raised, it will finalize the currently running clinical study to assess the usability of their system and measure market acceptance. Based on these results, Vivior will register the system in Europe and the US to make it available to clinics, surgeons and patients.